Brett Perry
Contributor
Healthcare innovation from the operator's side: regenerative medicine, peptides and GLP-1 access, and what reaches a clinic before it reaches a headline.
Brett Perry is a healthcare entrepreneur and CEO and Co-Founder of Blue Atlas Biologics, a healthcare technology company specializing in electronic prescribing, prescription routing, and access to emerging therapies. The company's platform serves more than 1,000 clinics nationwide, supporting providers in the growing fields of peptides, GLP-1 medications, and regenerative medicine.
With a background spanning engineering, finance, and healthcare, Brett has developed ventures in financial recovery and regenerative medicine, including wound care, stem cells, and exosome technologies. His experience includes representing more than 10,000 businesses and over $8 billion in transactions associated with the Visa/Mastercard interchange settlement.
Brett holds a bachelor's degree in Mechanical and Aerospace Engineering from the University at Buffalo, where he competed as a Division I wrestler. His interests include human performance, longevity, healthcare innovation, and emerging wellness technologies.
Brett is CEO and Co-Founder of Blue Atlas Biologics, whose platform handles electronic prescribing and prescription routing for peptides, GLP-1 medications and regenerative therapies. Those are subjects this desk covers, so he has a commercial interest in them. Worth knowing when you weigh what he tells you.
Articles by Brett Perry
- Palladium membranes destroy PFAS in water, not just filter them out
A team at Arizona State University and four partner institutions has built membranes that capture six regulated 'forever chemicals' and chemically break them apart, rather than concentrating them...